top of page
News
Jan 2026 - Launch of MitoStem™
Commercial launch of MitoStem™, our first ex vivo reagent designed to enhance cell therapy performance by increasing durable, stem-like T cell populations.
Oct 2025 - Best European Healthcare Startup Award
Recognized at HWL Luxembourg for our pioneering work in mitochondrial reprogramming and its therapeutic potential across multiple disease areas.
Feb 2025 - Landmark publication validates mitochondrial reprogramming approach
​MPC Therapeutics’ research published in Molecular Therapy: Oncology demonstrates that MITO-66 enhances CAR T cell persistence and antitumor efficacy by inducing a stem cell-like memory phenotype.
Feb 2024 - Opening of MPC Therapeutics’ new laboratory at La Tulipe
MPC Therapeutics opens its new laboratory at La Tulipe, strengthening its internal R&D capabilities and accelerating the development of metabolic solutions for cell therapy manufacturing.
bottom of page